Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIB4920 Phase 1b in RA
NCT02780388Phase 1Completed
- Sponsor
- Amgen
- Start
- May 2016
- Primary completion
- May 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of dazodalibep in rheumatoid arthritis (RA) (5 arms), sponsored by Amgen. Primary endpoints: Treatment-emergent Adverse Events and Adverse Events of Special Interest. Started May 2016; status: completed.
02
Drugs
dazodalibep
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02780388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780388.